Biohaven licenses IgG degraders to Ono Pharma for Japan, select Asian markets
BHVN•Biohaven entered an exclusive licensing agreement with Ono Pharma covering Japan, South Korea, Taiwan and ASEAN countries, with $80 million upfront and a $20 million milestone payment anticipated within a year. Ono will also pay royalties of approximately 20% on net sales in the territory.
1. Licensing agreement
Biohaven granted Ono Pharma exclusive rights to its IgG degraders in Japan, South Korea, Taiwan and ASEAN countries. The agreement includes $80 million upfront and a $20 million milestone payment anticipated within a year, plus royalties of approximately 20% on net sales in the licensed territory.
2. Development and retained rights
The agreement covers lead candidate BHV-1300, in Phase 3 development for Graves' disease, and next-generation IgG degraders. Biohaven retained rights outside the licensed territory, including in the United States, Europe and China.
